Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Isogenica enters into an evaluation agreement with Pfizer


Cambridge, UK, September 16, 2008: Isogenica Ltd today announced that it entered into an agreement with Pfizer in which Isogenica’s CIS display technology will be evaluated by Pfizer for its ability to generate therapeutic peptide candidates. Financial terms of the agreement were not disclosed.

Isogenica's CIS display technology provides a novel and effective means of rapidly identifying peptides, polypeptides and antibodies that bind with high affinity and specificity to any given molecular target. The technology can also be used for enhancing the in vivo performance of peptide therapeutic and diagnostic products.

'We look forward to building a strong and fruitful relationship with Pfizer and in assisting them with their therapeutic discovery activities' said Dr. Kevin FitzGerald, Isogenica's CEO. 'We believe that CIS display technology provides a powerful new approach for the discovery of peptides, antibodies and proteins for therapeutic and other in vivo applications'

- Ends -


Notes to editors:

About Isogenica

Isogenica was formed in December 2000 to develop and commercialize innovative in vitro molecular evolution technologies. The company has entered into a number of agreements with large pharmaceutical and biotechnology companies and has its research facility in Cambridge UK.


Isogenica's core technology, CIS display, can be applied to the discovery of new antibody, peptide and polypeptide drug candidates, to the discovery of high specificity diagnostic compounds and to the isolation of target validation and other research reagents, purification reagents and environmental detection reagents.


Contact details:

Kevin FitzGerald, PhD MBA
Isogenica Ltd
+44 (0) 1223 496720
kevin.fitzgerald@isogenica.com


Katja Stout/ Holly Griffiths/ Benjamyn Tan
College Hill
+44 (0) 20 7866 7856
holly.griffiths@collegehill.com


Publisher Contact Information:

Isogenica
+44 (0) 1223 496720
kevin.fitzgerald@isogenica.com

Company profile of Isogenica
Past press releases of Isogenica.

Data


25,894
Tech investments
From our Online Data Service
16,759
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Jun 29€1.3MSecurity
Jun 28€2.2MDatabase
Jun 28€12.0MMaterials
Jun 28€5.5MBusiness applications
Jun 27€3.0MBiopharmaceuticals
Jun 27€10.0MEnergy related
Jun 27N/AWireless applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.